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Henry Miller’s opinion piece, Biotech’s deﬁning moments
[1],inthe February issueof Trendsin Biotechnology, raises
the important problem of how to deﬁne biotechnology and
some of the problems that deﬁnitional issues have created,
in his opinion, for regulation. He then turns to the report
OECD Biotechnology Statistics 2006 (http://www.oecd.org/
dataoecd/51/59/36760212.pdf), which he cites as an ‘egre-
gious and recent example of deﬁnitional dysfunction’ that
partly uses a broad deﬁnition of biotechnology that would
‘yield worthless results’. He concludes that ‘the data in the
OECD report are garbage’.
Being responsible for the report, we are bemused by
Miller’s scathing review. The irony is that we share his
concerns over the need to carefully deﬁne biotechnology –
which is precisely what the report does.
Miller’s main criticism is that the data are derived from
different and worthless deﬁnitions of biotechnology in
questionnaire surveys of ﬁrms. He notes, correctly, that
the OECD’s single deﬁnition of biotechnology can cover
everything from modern biotechnology to fermented foods.
He also seems dissatisﬁed with the OECD’s list-based
deﬁnition that asks ﬁrms if they are active in seven main
categories of modern biotechnology. For instance, the list-
based deﬁnition includes ‘DNA/RNA’ as a major category
and gives examples of relevant technologies, such as geno-
mics, pharmacogenomics, genetic engineering, and DNA
andRNAsequencing.Athirddeﬁnitionalfailing,according
to Miller, is that some surveys use other deﬁnitions of
biotechnology.
We agree with Miller that the single deﬁnition, when
used alone, is of minimal value, which is exactly why the
results in the report are not based on the single deﬁnition,
as noted in the methodology chapter. The OECD recom-
mends that national statistics ofﬁces provide survey
respondents with both the single and the list-based deﬁ-
nition of biotechnology [OECD (2005) A Framework for
Biotechnology Statistics; http://www.oecd.org/dataoecd/5/
48/34935605.pdf]. The list-based deﬁnition is essential
because it is the only way of limiting results to respondent
ﬁrms that are active in modern biotechnology.
The OECD report provides data for up to 26 countries on
biotechnology employment, sales and R&D expenditures in
ﬁrms. The results for 15 countries are based on ﬁrms that
meet the requirements of the OECD list-based deﬁnition,
while the results for an additional seven countries should
similarlybelimitedtoﬁrmsactiveinmodernbiotechnology,
giving largely comparable results for up to 22 countries.
Four countries did not limit their deﬁnition to modern
biotechnology (although they exclude fermented food and
other traditional products). This is clearly noted in the
methodology section and in the tables and ﬁgures.
Deﬁnitional problems, however, do not end at how
biotechnology is deﬁned. There are also serious issues over
how to deﬁne a biotechnology ﬁrm and biotechnology R&D,
employment and revenues. Many collections of biotechnol-
ogy statistics are limited to data on core or dedicated
biotechnology ﬁrms and assume that all revenues, employ-
ment and R&D within these ﬁrms are related to biotech-
nology. Survey research has consistently shown that thisis
not the case. Furthermore, failing to include the signiﬁcant
biotechnology activities of large diversiﬁed ﬁrms can result
in substantial underestimates of biotechnology activities.
These issues are fully discussed with examples in the
methodology section of the OECD report.
An important feature of the OECD report is that it
provides extensive information on factors that affect the
quality and comparability of national biotechnology stat-
istics. As an example, Table 1 is a modiﬁed extract for 21
countries of a table in the report that summarizes meth-
odological issues. It provides details on how biotechnology
is deﬁned, how a biotechnology ﬁrm is deﬁned, the sample
frame, the survey non-response rate and whether or not
the survey results were extrapolated to account for
sampling methods or non-respondents. The bar charts of
the report also use distinct patterns to identify major
differences that affect comparability. For example, the
chart for sales of biotechnology products clearly differen-
tiates between data for total sales of core biotechnology
ﬁrms, which includes sales of products that are not pro-
duced using biotechnology and excludes sales of biotech-
nology products by large diversiﬁed ﬁrms, versus more
accurate sales data for biotechnology-based products only
from all ﬁrms active in biotechnology.
The OECDis continuing towork with member countries
to standardize how biotechnology ﬁrms, sales, employ-
ment, R&D and other statistics are deﬁned. A future
Biotechnology Statistics report should require far fewer
footnotes to identify differences in methodologies or deﬁ-
nitions. Until then, we will continue to document fully
issues that can inﬂuence comparability and interpretation.
Of course, this does require the reader to review the
methodological chapter and the footnotes to the tables
and charts carefully.
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c Response rate Extrapolation
Australia 2003–2004 OECD R&D Yes R&D 86% Partial
d
Belgium 2003 OECD All I.n.a. Secondary 31% No
Canada 2003 OECD All Yes Secondary 80% Yes
China (Shanghai) 2003 Modern All I.n.a. Secondary 39% No
Denmark 2003 None given R&D Yes R&D 63% Yes
Finland 2003 Modern Core I.n.a. Secondary 71% Partial
d
France 2003 OECD R&D Yes R&D 72% Yes
Germany 2004 OECD All No Secondary 65% Yes
Iceland 2003 OECD R&D Yes R&D 100% N.r.
Israel 2002 OECD All No Secondary 96% Yes
Italy 2004 OECD R&D Yes R&D 50% No
Japan 2003 Mixed
f All No Secondary 76% No
Korea 2004 Modern
g All I.n.a. Sector 100% N.r.
New Zealand 2005 OECD All No Secondary 93% No
Norway 2003 OECD R&D Yes R&D 95% Yes
Poland 2004 OECD I.n.a. Yes I.n.a. 34% No
South Africa
e 2002–2003 Mixed All No Secondary 72% No
Spain 2004 OECD R&D Yes R&D 86% Yes
Sweden 2003 Modern Core Yes Secondary I.n.a. I.n.a.
Switzerland 2004 OECD R&D Yes R&D 81% Yes
United States 2003 OECD R&D Yes R&D 81% Partial
d
aAbbreviations: N.r., not relevant; i.n.a., information not available.
bR&D, ﬁrms that perform biotechnology R&D; all, includes all identiﬁed ﬁrms with biotechnology activities; core, limited to dedicated biotechnology ﬁrms.
cR&D, national R&D survey; secondary, combination of different sources to identify biotechnology ﬁrms; sector, all ﬁrms active in speciﬁc sectors.
dImputed or extrapolated results limited to selected ﬁrms or indicators, or to missing survey questions for respondents only.
eLarge ﬁrms in traditional biotechnology (fermented food products) were excluded, but some traditional and second generation biotechnology ﬁrms are included in the
sample.
fWherever possible, the results are limited to ‘modern’ biotechnology, but this could still include some second-generation or traditional biotechnology activity.
gCould include some second generation biotechnology.
AGORA initiative provides free agriculture journals to
developing countries
The Health Internetwork Access to Research Initiative (HINARI) of the WHO has launched a new
community scheme with the UN Food and Agriculture Organization.
As part of this enterprise, Elsevier has given hundreds of journals to Access to Global Online
Research in Agriculture (AGORA). More than 100 institutions are now registered for the scheme,
which aims to provide developing countries with free access to vital research that will ultimately
help increase crop yields and encourage agricultural self-sufficiency.
According to the Africa University in Zimbabwe, AGORA has been welcomed by both students
and staff. ‘‘It has brought a wealth of information to our fingertips’’, says Vimbai Hungwe. ‘‘The
information made available goes a long way in helping the learning, teaching and research
activities within the University. Given the economic hardships we are going through, it couldn’t
have come at a better time.’’
For more information, visit www.aginternetwork.org
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